Search results for "PHASE"

showing 10 items of 6344 documents

Effect on quality of life of cisplatin added to single-agent chemotherapy as first-line treatment for elderly patients with advanced non-small cell l…

2019

Abstract Objectives To evaluate the effect on quality of life (QOL) of the addition of cisplatin to single-agent chemotherapy in the treatment of elderly patients with advanced non-small cell lung cancer (NSCLC) enrolled in two parallel phase 3 trials, MILES-3 and MILES-4. Patients and methods Advanced NSCLC pts, >70 years old, performance status (PS) 0–1, were eligible. Patients were randomly assigned to chemotherapy without or with cisplatin. EORTC QLQ C30 and LC13 questionnaires were planned at baseline, end of cycle 1 and end of cycle 2 in both trials and were used for joint QOL analysis. Trial-specific data including questionnaires at non-shared time-points were used for additional ana…

0301 basic medicinePulmonary and Respiratory MedicineQuality of lifeMaleCancer Researchmedicine.medical_specialtyLung NeoplasmsNauseamedicine.medical_treatmentRandomizedNSCLCPhase 303 medical and health sciences0302 clinical medicineQuality of lifeInternal medicineSurveys and QuestionnairesCarcinoma Non-Small-Cell LungAntineoplastic Combined Chemotherapy ProtocolsmedicineHumansSurveys and QuestionnaireLung cancerAgedNeoplasm StagingCisplatinAged 80 and overChemotherapyAntineoplastic Combined Chemotherapy ProtocolPerformance statusbusiness.industryAlopeciamedicine.diseaseDysphagiaLung Neoplasm030104 developmental biologyTreatment OutcomeOncology030220 oncology & carcinogenesisVomitingStomatitis AphthousFemalemedicine.symptomCisplatinbusinessElderly patientStomatitis Aphthoumedicine.drugHuman
researchProduct

Transcription factor NRF2 as a therapeutic target for chronic diseases: a systems medicine approach

2018

Systems medicine has a mechanism-based rather than a symptom- or organ-based approach to disease and identifies therapeutic targets in a nonhypothesis-driven manner. In this work, we apply this to transcription factor nuclear factor (erythroid-derived 2)-like 2 (NRF2) by cross-validating its position in a protein-protein interaction network (the NRF2 interactome) functionally linked to cytoprotection in low-grade stress, chronic inflammation, metabolic alterations, and reactive oxygen species formation. Multiscale network analysis of these molecular profiles suggests alterations of NRF2 expression and activity as a common mechanism in a subnetwork of diseases (the NRF2 diseasome). This netw…

0301 basic medicineRMSystems AnalysisNF-E2-Related Factor 2MedicinaNF-KAPPA-BAnti-Inflammatory AgentsTYPE-2 DIABETES-MELLITUSGENE PROMOTER POLYMORPHISMDiseaseComputational biologyInteractomeenvironment and public healthGLYCOGEN-SYNTHASE KINASETUMOR-SUPPRESSOR PTENNRF203 medical and health sciencesDrug DiscoveryAnimalsHumansTherapeutic targetsMedicineMolecular Targeted TherapyBardoxolone methylPLACEBO-CONTROLLED PHASE-3PharmacologyMechanism (biology)Drug discoverybusiness.industryDrug RepositioningRChronic inflammationrespiratory systemHEME OXYGENASE 1PROTEIN-PROTEIN INTERACTION3. Good healthSystems medicineDrug repositioning030104 developmental biologyDrug developmentEXPERIMENTAL AUTOIMMUNE ENCEPHALOMYELITISChronic DiseaseSystems medicineMolecular MedicineFUMARIC-ACID ESTERSbusiness
researchProduct

Model Based Targeting of IL-6-Induced Inflammatory Responses in Cultured Primary Hepatocytes to Improve Application of the JAK Inhibitor Ruxolitinib

2017

IL-6 is a central mediator of the immediate induction of hepatic acute phase proteins (APP) in the liver during infection and after injury, but increased IL-6 activity has been associated with multiple pathological conditions. In hepatocytes, IL-6 activates JAK1-STAT3 signaling that induces the negative feedback regulator SOCS3 and expression of APPs. While different inhibitors of IL-6-induced JAK1-STAT3-signaling have been developed, understanding their precise impact on signaling dynamics requires a systems biology approach. Here we present a mathematical model of IL-6-induced JAK1-STAT3 signaling that quantitatively links physiological IL-6 concentrations to the dynamics of IL-6-induced …

0301 basic medicineRuxolitinibruxolitinibPhysiologySystems biologyRegulatorBiologyPharmacology: Biochemistry biophysics & molecular biology [F05] [Life sciences]lcsh:Physiology03 medical and health sciencesMediatoracute phase responsePhysiology (medical)medicineSOCS3primary hepatocytes: Biochimie biophysique & biologie moléculaire [F05] [Sciences du vivant]Original ResearchIL-6lcsh:QP1-981Acute-phase proteinmathematical modelingJAK-STAT signaling pathwayCell biology030104 developmental biologySignal transductionmedicine.drugFrontiers in Physiology
researchProduct

A phase 2 study of galunisertib (TGF-Β R1 inhibitor) and sorafenib in patients with advanced hepatocellular carcinoma (HCC).

2017

4097 Background: TGFβ signaling is associated with HCC progression. Inhibition of TGFβ R1 potentiates activity of sorafenib in in-vitro and in-vivo models. Here we report the clinical activity of galunisertib (G) plus sorafenib (S) in pts with incurable HCC and no prior systemic therapy. Methods: Eligibility criteria included incurable HCC with measurable disease per RECIST 1.1, no prior systemic therapy, Child Pugh A, ECOG PS ≤1.G was administered as 80 mg PO BID (lead-in Cohort 1) or 150 mg PO BID (lead-in Cohort 2 and expansion cohort), as intermittent dosing of 14 days on/off (28 days = 1 cycle). S was administered continuously as a 400 mg PO BID. Primary objective was to characterize …

0301 basic medicineSorafenibCancer ResearchPathologymedicine.medical_specialtybusiness.industryPhases of clinical researchmedicine.disease03 medical and health sciences030104 developmental biology0302 clinical medicineOncology030220 oncology & carcinogenesisHepatocellular carcinomaCancer researchMedicineGalunisertibIn patientbusinessTransforming growth factormedicine.drugJournal of Clinical Oncology
researchProduct

The role of molecular enrichment on future therapies in hepatocellular carcinoma

2017

Summary Hepatocellular carcinomas (HCCs) are characterised by considerable phenotypic and molecular heterogeneity. Treating HCC and designing clinical trials are particularly challenging because co-existing liver disease, present in most patients, limits aggressive therapeutic options. Positive results in recent phase III clinical trials have confirmed the high value of anti-angiogenic therapies for HCC in both first (sorafenib and lenvatinib) and second line (regorafenib and cabozantinib) treatment modalities. However, failure of several large randomised controlled clinical trials over the last 10 years underlines the necessity for innovative treatment strategies and implementation of tran…

0301 basic medicineSorafenibOncologymedicine.medical_specialtyCarcinoma HepatocellularCabozantinibPhases of clinical research03 medical and health scienceschemistry.chemical_compound0302 clinical medicineInternal medicineRegorafenibmedicineHumansMolecular Targeted TherapyClinical Trials as TopicHepatologybusiness.industryLiver NeoplasmsPrecision medicinemedicine.diseasedigestive system diseasesClinical trial030104 developmental biologychemistry030220 oncology & carcinogenesisHepatocellular carcinomaImmunotherapybusinessLenvatinibmedicine.drugJournal of Hepatology
researchProduct

Comparison of Two Solid-Phase Extraction (SPE) Methods for the Identification and Quantification of Porcine Retinal Protein Markers by LC-MS/MS

2018

Proper sample preparation protocols represent a critical step for liquid chromatography-mass spectrometry (LC-MS)-based proteomic study designs and influence the speed, performance and automation of high-throughput data acquisition. The main objective of this study was to compare two commercial solid-phase extraction (SPE)-based sample preparation protocols (comprising SOLA&micro

0301 basic medicineSwineGeneral Mathematicssample clean-upProteomicsMass spectrometry01 natural sciencesCatalysisRetinaArticlelcsh:ChemistryInorganic Chemistry03 medical and health scienceschemistry.chemical_compoundglaucoma animal modelZIPTIP® C18 pipette tipsTandem Mass SpectrometryLiquid chromatography–mass spectrometryTrifluoroacetic acidAnimalsSample preparationSolid phase extractionPhysical and Theoretical ChemistryEye Proteinslcsh:QH301-705.5Molecular BiologySpectroscopymass spectrometryZIPTIP<sup>®</sup> C18 pipette tipsReproducibilityChromatographyChemistryApplied Mathematics010401 analytical chemistryOrganic ChemistrySolid Phase ExtractionExtraction (chemistry)PipettebiomarkersGlaucomaGeneral Medicine0104 chemical sciencesComputer Science Applications030104 developmental biologylcsh:Biology (General)lcsh:QD1-999SOLAμTM HRP SPE spin platesPeptidesChromatography LiquidInternational Journal of Molecular Sciences
researchProduct

An overview on anti-tubulin agents for the treatment of lymphoma patients

2020

Anti-tubulin agents constitute a large class of compounds with broad activity both in solid tumors and hematologic malignancies, due to the interference with microtubule dynamics. Since microtubules play crucial roles in the regulation of the mitotic spindles, the interference with their function usually leads to a block in cell division with arrest at the metaphase/anaphase junction of mitosis, followed to apoptosis. This explains the reason why tubulin-binding agents (TBAs) proved to be extremely active in patients with cancer. Several anti-tubulin agents are indicated in the treatment of patients with lymphomas both alone and in combination chemotherapy regimens. The article reviews the …

0301 basic medicineVinca alkaloidsLymphomaMitosisAntineoplastic AgentsApoptosismacromolecular substancesMicrotubulesAntibody drug conjugatesTaxanes03 medical and health sciences0302 clinical medicineTubulinMicrotubulemedicineAnimalsHumansMaytansinePharmacology (medical)MetaphaseMitosisAnaphasePharmacologybiologybusiness.industryCancerCombination chemotherapymedicine.diseaseTubulin ModulatorsLymphoma030104 developmental biologyTubulinEpothilones030220 oncology & carcinogenesisbiology.proteinCancer researchDolastatinsbusinessPharmacology &amp; Therapeutics
researchProduct

Fractional hereditariness of lipid membranes: Instabilities and linearized evolution

2016

In this work lipid ordering phase changes arising in planar membrane bilayers is investigated both accounting for elas- ticity alone and for effective viscoelastic response of such assemblies. The mechanical response of such membranes is studied by minimizing the Gibbs free energy which penalizes perturbations of the changes of areal stretch and their gradients only [1]. As material instabilities arise whenever areal stretches characterizing homogeneous configurations lie inside the spinoidal zone of the free energy density, bifurcations from such configurations are shown to occur as oscillatory perturbations of the in-plane displacement. Experimental observations [2] show a power-law in-pl…

0301 basic medicineViscoelastic lipid membranePhase transitionMembrane Fluidity0206 medical engineeringLipid BilayersBiomedical EngineeringSeparation of variablesFOS: Physical sciences02 engineering and technologyviscoelastic lipid membranesCondensed Matter - Soft Condensed Matterfractional hereditary lipid membranesViscoelasticityFractional hereditary lipid membraneMaterial instabilitieBiomaterials03 medical and health sciencessymbols.namesakeFractional hereditary lipid membranes; Material instabilities; Phase transitions; Viscoelastic lipid membranes; Biomaterials; Biomedical Engineering; Mechanics of MaterialsVariational principleElasticity (economics)Phase transitionMembranesChemistryOscillationTime evolutionBiomaterial020601 biomedical engineeringElasticityGibbs free energyphase transitions030104 developmental biologyClassical mechanicsModels ChemicalMechanics of MaterialssymbolsSoft Condensed Matter (cond-mat.soft)material instabilitiesSettore ICAR/08 - Scienza Delle Costruzionifractional hereditary lipid membranes viscoelastic lipid membranes phase transitions material instabilities
researchProduct

Phase separations induced by a trapping potential in one-dimensional fermionic systems as a source of core-shell structures

2018

Ultracold fermionic gases in optical lattices give a great opportunity for creating different types of novel states. One of them is phase separation induced by a trapping potential between different types of superfluid phases. The core-shell structures, occurring in systems with a trapping potential, are a good example of such separations. The types and the sequences of phases which emerge in such structures can depend on spin-imbalance, shape of the trap and on-site interaction strength. In this work, we investigate the properties of such structures within an attractive Fermi gas loaded in the optical lattice, in the presence of the trapping potential and their relations to the phase diagr…

0301 basic medicineWork (thermodynamics)lcsh:MedicineFOS: Physical sciencesTrappingMolecular physicsArticleSuperconducting properties and materialsTrap (computing)Superfluidity03 medical and health sciences0302 clinical medicinePhase (matter)lcsh:ScienceUltracold gasesPhase diagramPhysicsCondensed Matter::Quantum GasesOptical latticeMultidisciplinarylcsh:R030104 developmental biologyQuantum Gases (cond-mat.quant-gas)lcsh:QCondensed Matter - Quantum GasesFermi gas030217 neurology & neurosurgery
researchProduct

The Antisense RNA Approach: a New Application for In Vivo Investigation of the Stress Response of Oenococcus oeni, a Wine-Associated Lactic Acid Bact…

2015

ABSTRACT Oenococcus oeni is a wine-associated lactic acid bacterium mostly responsible for malolactic fermentation in wine. In wine, O. oeni grows in an environment hostile to bacterial growth (low pH, low temperature, and ethanol) that induces stress response mechanisms. To survive, O. oeni is known to set up transitional stress response mechanisms through the synthesis of heat stress proteins (HSPs) encoded by the hsp genes, notably a unique small HSP named Lo18. Despite the availability of the genome sequence, characterization of O. oeni genes is limited, and little is known about the in vivo role of Lo18. Due to the lack of genetic tools for O. oeni , an efficient expression vector in O…

0301 basic medicine[SDV.BIO]Life Sciences [q-bio]/Biotechnology[ SDV.AEN ] Life Sciences [q-bio]/Food and Nutrition030106 microbiologyLactobacillus-plantarumWineEscherichia-coliApplied Microbiology and Biotechnologymolecular characterization03 medical and health sciencesGrowth-phaseBacterial ProteinsMembrane stabilizationHeat shock protein[SDV.BBM.GTP]Life Sciences [q-bio]/Biochemistry Molecular Biology/Genomics [q-bio.GN]Antisense TechnologyGene expression[SDV.IDA]Life Sciences [q-bio]/Food engineeringMalolactic fermentationEnvironmental MicrobiologyRNA AntisenseGene-expressionLactic AcidHeat-Shock ProteinsOenococcusOenococcus oeniLeuconostoc-oenosEcologybiologyEthanolLactococcus lactisMalolactic fermentation[ SDV.BIO ] Life Sciences [q-bio]/BiotechnologyGene Expression Regulation Bacterialbiology.organism_classification[SDV.MP.BAC]Life Sciences [q-bio]/Microbiology and Parasitology/BacteriologyAntisense RNABiochemistryLactococcus-lactisHeat-shock-proteinFermentationOenococcusFood ScienceBiotechnology
researchProduct